579 related articles for article (PubMed ID: 28318043)
1. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
[TBL] [Abstract][Full Text] [Related]
2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
[TBL] [Abstract][Full Text] [Related]
5. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
Flanagan E; Gibson PR; Wright EK; Moore GT; Sparrow MP; Connell W; Kamm MA; Begun J; Christensen B; De Cruz P; Shelton E; Dowling D; Andrews JM; Brown SJ; Niewiadomski O; Ward MG; Rosella O; Rosella G; Kiburg KV; Ross AL; Bell SJ;
Aliment Pharmacol Ther; 2020 Nov; 52(10):1551-1562. PubMed ID: 32981127
[TBL] [Abstract][Full Text] [Related]
6. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
Grišić AM; Dorn-Rasmussen M; Ungar B; Brynskov J; Ilvemark JFKF; Bolstad N; Warren DJ; Ainsworth MA; Huisinga W; Ben-Horin S; Kloft C; Steenholdt C
United European Gastroenterol J; 2021 Feb; 9(1):91-101. PubMed ID: 33079627
[TBL] [Abstract][Full Text] [Related]
7. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
8. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels.
Bond A; Asher R; Jackson R; Sager K; Martin K; Kneebone A; Philips S; Taylor W; Subramanian S
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):271-6. PubMed ID: 26657455
[TBL] [Abstract][Full Text] [Related]
10. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
12. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
13. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
14. Biologic Therapeutic Drug Monitoring in Australia.
J Connor S
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():8-9. PubMed ID: 26990573
[No Abstract] [Full Text] [Related]
15. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy.
Schnitzler F; Fidder H; Ferrante M; Ballet V; Noman M; Van Assche G; Spitz B; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2011 Sep; 17(9):1846-54. PubMed ID: 21830263
[TBL] [Abstract][Full Text] [Related]
16. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
[TBL] [Abstract][Full Text] [Related]
17. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
18. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
[TBL] [Abstract][Full Text] [Related]
19. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
[TBL] [Abstract][Full Text] [Related]
20. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.
Park KT; Sin A; Wu M; Bass D; Bhattacharya J
Inflamm Bowel Dis; 2014 Jul; 20(7):1242-9. PubMed ID: 24846718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
